A partial length recombinant Beta actin protein (amino acids 1-200) was used as the immunogen for this antibody.
Alternative Names:
Actin, cytoplasmic 1, ACTB
B-actin (ACTB) has traditionally been regarded as an endogenous housekeeping gene and has been widely used as a reference gene/protein in quantifying expression levels in tumors. It supports fundamental cellular processes in healthy and diseased cells including cell adhesion, migration, cytokinesis and maintenance of cell polarity. However, B-actin is closely associated with a variety of cancers and accumulating evidence indicates that B-actin is de-regulated in liver, melanoma, renal, colorectal, gastric, pancreatic, esophageal, lung, breast, prostate, ovarian cancers, leukemia and lymphoma. This protein is generally found to be up-regulated in the majority of tumor cells and tissues.
Figure-1: Western blot analysis of Beta actin. Anti-Beta actinantibody (11-13012)was used at 4 µg/ml on1) Raw, 2) 3T3, 3) Hela and 4)U87 lysates.
Figure-2: Western blot analysis of Beta actin. Anti-Beta actinantibody (11-13012)was used at 1 µg/ml on(1) Miapica-2, (2) HepG2, (3) Jurkat, (4) HCT-116, (5) 293, (6) THP1, (7) A549, (8) C2C12 and (9) MCF-7 lysates.
Figure-3: Western blot analysis of Beta actin. Anti-Beta actinantibody (11-13012)was used at 2 µg/ml on(1) Rat Spleen, (2) Human Intestine, (3) Mouse Spleen and (4) BV2 lysates.
* VAT and and shipping costs not included. Errors and price changes excepted
